For the quarter ending 2026-03-31, SILO had -$858,014 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net realized (gain) loss on short-term investments | - | 0 | 3,911 |
| Net loss | 1,699,051 | -1,110,438 | -2,235,730 |
| Amortization expense | -5,566 | 2,938 | 5,565 |
| Amortization of prepaid stock-based professional fees | 26,712 | - | - |
| Unrealized loss on short-term tokenized investment funds | -2,060 | - | - |
| Staking income on crypto assets | 191 | - | - |
| Unrealized loss on crypto assets, at fair value | -50,658 | -2,690 | - |
| Impairment loss on crypto assets, at cost | 29,911 | - | - |
| Stock-based compensation | -8,093 | 47,267 | 17,445 |
| Common stock issued for acquired technology expensed | 195,775 | 518,225 | - |
| Prepaid expenses and other current assets | -38,239 | 56,592 | 79,186 |
| Accounts payable and accrued expenses | 989,920 | -341,558 | -593,700 |
| Deferred revenue | 36,051 | -18,025 | -36,051 |
| Net cash used in operating activities | 3,058,438 | -955,493 | -2,925,568 |
| Proceeds from the sale of short-term debt investments | - | 0 | 1,315,653 |
| Purchases of short-term debt investments | -57,910 | 20,501 | 56,170 |
| Proceeds from the sale of crypto assets | 45,188 | - | - |
| Purchases of crypto assets | -24,983 | 74,973 | - |
| Net cash (used in) provided by investing activities | -1,187,572 | -95,474 | 1,259,483 |
| Net proceeds from sale of common stock and pre-funded warrants | - | 0 | 1,593,897 |
| Purchase of treasury stock | - | - | 0 |
| Proceeds from exercise of warrants, net of offering costs | - | 634,922 | 500,061 |
| Net cash provided by financing activities | - | 634,922 | 2,093,958 |
| Net decrease in cash and cash equivalents | -858,014 | -416,045 | 427,873 |
| Cash and cash equivalents - beginning of the period | 3,917,627 | 3,905,799 | - |
| Cash and cash equivalents - end of the period | 3,902,514 | 3,917,627 | - |
Silo Pharma, Inc. (SILO)
Silo Pharma, Inc. (SILO)